Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company said the safety profile remained consistent with earlier studies and was considered manageable
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
The company hosted Symbiosis 2026 at its 2-acre manufacturing facility in Bengaluru, inaugurated in 2024
New Gurugram centre is India's first clinical Prevention Centre with 2 state of the art MRI machines and a capacity of 2000 scans a month
Subscribe To Our Newsletter & Stay Updated
